已发表论文

大剂量替加环素治疗鹦鹉热衣原体引起的进行性肺炎:病例系列和文献综述

 

Authors Wang L, Liu J, Peng L

Received 8 November 2022

Accepted for publication 23 December 2022

Published 5 January 2023 Volume 2023:16 Pages 115—124

DOI https://doi.org/10.2147/IDR.S393647

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Suresh Antony

Purpose: To summarize the clinical characteristics of progressive pneumonia caused by Chlamydia psittaci (C. psittaci ) and to explore the effect of high-dose tigecycline on severe C psittaci .
Patients and Methods: We retrospectively analyzed the clinical characteristics, treatment, and outcomes of three progressive pneumonia patients caused by C. psittaci in our hospital in the past three years.
Results: All three patients showed high fever and progressive dyspnea, and all of them were finally diagnosed by bronchoalveolar lavage fluid (BALF) of metagenomic next-generation sequencing (mNGS). Case 1 rapidly developed into multilobar infiltration after raising a parrot with a normal appearance one week before. Respiratory failure occurred despite the use of moxifloxacin, requiring non-invasive ventilator-assisted ventilation. Case 2 developed discomfort one day after sightseeing in the forest park. Moxifloxacin was ineffective for her and she quickly developed respiratory failure, requiring invasive ventilator-assisted ventilation. Case 3 kept chickens and ducks at home. Respiratory failure and renal failure still occurred rapidly despite the use of doxycycline, requiring invasive ventilator-assisted ventilation and continuous renal replacement therapy (CRRT). After adjusting the antibiotic to high-dose tigecycline (100mg, I.V., q12h), all three patients were treated effectively and no side effects occurred.
Conclusion: C. psittaci pneumonia is one of the causes of progressive pneumonia. High-dose tigecycline is safe and effective for the treatment of severe C. psittaci .
Keywords: Chlamydia psittaci , progressive pneumonia, metagenomic next-generation sequencing, high-dose tigecycline